Literature DB >> 21326031

Visual inspection with acetic acid in cervical cancer screening.

Melek Ardahan1, Ayla Bayik Temel.   

Abstract

BACKGROUND: Visual inspection with acetic acid (VIA) is an attractive screening method for early-phase cervical cancer in underdeveloped countries.
OBJECTIVE: This study addressed the validity of VIA in cervical cancer screening by comparing results with colposcopy findings.
METHODS: Of 350 women screened at the Ege University clinic using the Papanicolaou test, colposcopy and VIA were used additionally to screen 50 of these women. Colposcopy, VIA, and Papanicolaou test results were compared. A sociodemographic data questionnaire and a VIA questionnaire were used.
RESULTS: When VIA findings were compared with Papanicolaou test findings, the sensitivity of VIA was 82.14%, specificity was 50.00%, positive predictive value (PPV) was 67.64%, and negative predictive value (NPV) was 68.75%. When the method of VIA was compared with colposcopy, VIA had a sensitivity of 85.29%, specificity of 68.75%, PPV of 85.29%, and NPV of 68.75%.
CONCLUSIONS: In the screening of cervical cancer, the sensitivity of VIA was high, whereas the corresponding specificity was only at an acceptable level. The PPV and NPV of VIA were found to be high. In other words, the validity of VIA during early-phase screening is high in terms of sensitivity and acceptable for specificity and predictive values. IMPLICATIONS FOR PRACTICE: Visual inspection with acetic acid is an acceptable screening method for cervical cancer and seems to be an efficient and cost-effective method to detect high-level dysplasia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21326031     DOI: 10.1097/NCC.0b013e3181efe69f

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  7 in total

1.  Cervical Cancer Screening Program by Visual Inspection: Acceptability and Feasibility in Health Insurance Companies.

Authors:  Apollinaire G Horo; Judith Didi-Kouko Coulibaly; Abdoul Koffi; Boris Tchounga; Konan Seni; Kacou Edèle Aka; Mamourou Kone
Journal:  Obstet Gynecol Int       Date:  2015-06-18

2.  Beliefs, perceptions and health-seeking behaviours in relation to cervical cancer: a qualitative study among women in Uganda following completion of an HPV vaccination campaign.

Authors:  Olivia Topister Hasahya; Vanja Berggren; Douglas Sematimba; Rose Chalo Nabirye; Edward Kumakech
Journal:  Glob Health Action       Date:  2016-02-16       Impact factor: 2.640

Review 3.  Low level of knowledge about cervical cancer among Ethiopian women: a systematic review and meta-analysis.

Authors:  Awoke Derbie; Daniel Mekonnen; Eyaya Misgan; Yihun Mulugeta Alemu; Yimtubezinash Woldeamanuel; Tamrat Abebe
Journal:  Infect Agent Cancer       Date:  2021-02-10       Impact factor: 2.965

4.  Prevalence of oncogenic human papillomavirus (HPV 16/18) infection, cervical lesions and its associated factors among women aged 21-49 years in Amhara region, Northern Ethiopia.

Authors:  Minwuyelet Maru Temesgen; Tefera Alemu; Birtukan Shiferaw; Seid Legesse; Taye Zeru; Mahteme Haile; Tesfaye Gelanew
Journal:  PLoS One       Date:  2021-03-24       Impact factor: 3.240

5.  Cervical cancer and precancerous cervical lesions detected using visual inspection with acetic acid at Livingstone Teaching Hospital.

Authors:  Valerie Hayumbu; Joy Hangoma; Benson Malambo Hamooya; Malan Malumani; Sepiso Kenias Masenga
Journal:  Pan Afr Med J       Date:  2021-12-17

6.  Development of label-free gold nanoparticle based rapid colorimetric assay for clinical/point-of-care screening of cervical cancer.

Authors:  Tejaswini Appidi; Sushma V Mudigunda; Suseela Kodandapani; Aravind Kumar Rengan
Journal:  Nanoscale Adv       Date:  2020-10-07

Review 7.  HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review.

Authors:  Awoke Derbie; Daniel Mekonnen; Yimtubezinash Woldeamanuel; Xaveer Van Ostade; Tamrat Abebe
Journal:  Infect Agent Cancer       Date:  2020-02-07       Impact factor: 2.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.